CASE-001

Section 1 of 4

What the payer refused, and why

Patient

Jeromy Upton

Payer

NORTHBECK HEALTH PLAN

Service denied

Continuous glucose monitoring system, receiver and transmitter CPT/HCPCS E2103 · ICD-10 E11.65 · dated 6 July 2026
Continuous glucose monitor sensors, one month supply CPT/HCPCS A4239 · ICD-10 E11.65 · dated 6 July 2026

Payer's stated reason

The clinical information submitted does not establish that the requested continuous glucose monitoring system is medically necessary under the plan's applicable medical policy. Specifically, the submitted documentation does not establish that the member is treated with an intensive insulin regimen as that term is defined in the applicable policy, and does not establish that self-monitoring of blood glucose has been insufficient to guide therapy.

Section 2 of 4

The clinical argument, criterion by criterion

The patient is a 59-year-old male with type 2 diabetes mellitus on a multiple daily injection insulin regimen. Due to ongoing hypoglycaemia and impaired awareness, his endocrinologist recommended a continuous glucose monitor (CGM) during an office visit on May 19, 2026. The patient subsequently completed device training with a diabetes educator on June 11, 2026.

Each row is a requirement in the payer's own policy, the verdict reached on it, and the chart text that verdict rests on. 6 of 11 are satisfied with evidence. Read the quotations against what you remember of the care. There is no confidence column: nothing you are about to sign changes at ninety-four percent rather than eighty-eight.
Criterion	Verdict	Chart evidence
NBH-ENDO-031-3.1 The member has a documented diagnosis of type 1 diabetes mellitus, or type 2 diabetes mellitus treated with an intensive insulin regimen consisting of three or more injections of insulin per day or continuous subcutaneous insulin infusion.	Satisfied The patient is documented to have type 2 diabetes mellitus treated with a multiple daily injection regimen consisting of four injections of insulin per day total (one glargine nightly plus three lispro with meals).	Fifty-nine year old man with type 2 diabetes mellitus of nine years' duration, currently on a multiple daily injection regimen: insulin glargine 38 units nightly plus insulin lispro three times daily with meals, four injections per day total enc/2026-05-19/endocrinology
NBH-ENDO-031-3.2 The member, or the member's caregiver, has completed a documented training session on the use and interpretation of the requested device, or such training is scheduled prior to dispensing.	Satisfied The patient and his spouse completed a documented training session on the use and interpretation of the continuous glucose monitoring system.	Completed a forty-five minute structured training session with the patient and his spouse on the use, application, calibration and interpretation of the prescribed continuous glucose monitoring system. enc/2026-06-11/diabetes-education
NBH-ENDO-031-3.3 The member has had at least one in-person or telehealth evaluation with the treating clinician within the six months preceding the request, at which diabetes management was addressed.	Satisfied The patient had a telehealth visit with his endocrinologist on July 14, 2026, which is within the preceding six months, and during which his diabetes management was discussed in full.	Interim review pending device authorisation. Patient reports one further episode of hypoglycaemia in early July, again without warning symptoms, glucose 52 mg/dL on his spouse's meter. Diabetes management discussed in full: insulin regimen unchanged, fingerstick frequency unchanged at two to three per day. enc/2026-07-14/endocrinology
NBH-ENDO-031-3.4 At least one of the following is documented within the twelve months preceding the request: - A hemoglobin A1c result of 7.0 percent or greater; or - One or more episodes of level 2 hypoglycaemia, defined as a blood glucose measurement below 54 mg/dL; or - One or more episodes of documented hypoglycaemia unawareness; or - One or more emergency department visits or hospital admissions for hyperglycaemia or diabetic ketoacidosis.	Insufficient documentation Downgraded automatically: the criterion was marked satisfied but no surviving chart evidence supports it. The patient's Hemoglobin A1c was documented as 8.6% on May 19, 2026, which is greater than the 7.0% threshold.	No chart evidence cited
NBH-ENDO-031-3.5 The prescribing clinician has documented that self-monitoring of blood glucose by fingerstick has been insufficient to guide therapy adjustment, or that the member is unable to perform fingerstick testing at the frequency the treatment plan requires.	Satisfied The treating clinician explicitly documented that the fingerstick monitoring the patient is able to sustain is insufficient to guide safe titration of his mealtime insulin.	Because his overnight and mid-shift excursions are going undetected, fingerstick monitoring at the frequency he is able to sustain is insufficient to guide safe titration of his mealtime insulin. enc/2026-05-19/endocrinology
NBH-ENDO-031-4.1 A clinical note from the treating clinician dated within six months of the request that states the diabetes type, the current insulin regimen, and the clinical rationale for continuous monitoring.	Satisfied The endocrinology progress note dated May 19, 2026, details the patient's type 2 diabetes diagnosis, current four-injection daily insulin regimen, and the clinical rationale for CGM use due to undetected overnight and mid-shift excursions.	Fifty-nine year old man with type 2 diabetes mellitus of nine years' duration, currently on a multiple daily injection regimen: insulin glargine 38 units nightly plus insulin lispro three times daily with meals, four injections per day total, alongside metformin 1000 mg twice daily. enc/2026-05-19/endocrinology Because his overnight and mid-shift excursions are going undetected, fingerstick monitoring at the frequency he is able to sustain is insufficient to guide safe titration of his mealtime insulin. enc/2026-05-19/endocrinology
NBH-ENDO-031-4.2 The most recent hemoglobin A1c result with its collection date, or, where section 3.4 is met by hypoglycaemia rather than by A1c, glucose logs or clinical notes documenting those episodes with dates.	Insufficient documentation Downgraded automatically: the criterion was marked satisfied but no surviving chart evidence supports it. The chart records the patient's most recent HbA1c result of 8.6% with its collection date of May 19, 2026.	No chart evidence cited
NBH-ENDO-031-4.3 A record of device training, or a scheduled training appointment with its date.	Satisfied A telehealth visit with diabetes education on June 11, 2026, confirms the patient completed a structured training session for the continuous glucose monitoring system.	Completed a forty-five minute structured training session with the patient and his spouse on the use, application, calibration and interpretation of the prescribed continuous glucose monitoring system. enc/2026-06-11/diabetes-education
NBH-ENDO-031-6.1 Continuous glucose monitoring for a member with diabetes mellitus who is not treated with insulin, except where section 3.4 is met by documented level 2 hypoglycaemia attributable to a sulfonylurea or meglitinide.	Not satisfied The patient is on a multiple daily injection insulin regimen, meaning he is treated with insulin. Thus, this exclusion is not met.	Fifty-nine year old man with type 2 diabetes mellitus of nine years' duration, currently on a multiple daily injection regimen: insulin glargine 38 units nightly plus insulin lispro three times daily with meals, four injections per day total enc/2026-05-19/endocrinology
NBH-ENDO-031-6.2 Replacement of a functioning device before the end of its manufacturer-stated service life, absent documented loss or irreparable damage.	Not applicable The provider is prescribing an initial continuous glucose monitoring system for the patient, so the exclusion regarding the replacement of an existing device does not apply.	Plan: prescribe a personal continuous glucose monitoring system with alerts for hypoglycaemia; refer to the diabetes education team for device training; continue current insulin doses pending sensor data; return in three months. enc/2026-05-19/endocrinology
NBH-ENDO-031-6.3 More than one personal continuous glucose monitoring system per member concurrently.	Not applicable The provider has prescribed a single personal continuous glucose monitoring system, so the exclusion for concurrent multiple systems is not applicable.	Plan: prescribe a personal continuous glucose monitoring system with alerts for hypoglycaemia; refer to the diabetes education team for device training; continue current insulin doses pending sensor data; return in three months. enc/2026-05-19/endocrinology

Section 3 of 4

The letter that goes out over your name — attempt 3

Subject: Appeal of Coverage Denial for Continuous Glucose Monitoring System (Claim: CLM-2026-0714-33902 / Member ID: NBH-4417-99083)

RE: Appeal of Coverage Denial Claim Number: CLM-2026-0714-33902 Member ID: NBH-4417-99083 Service Denied: Continuous glucose monitoring system, receiver and transmitter To Northbeck Health Plan Appeals Department, We are writing on behalf of the member to appeal the coverage denial for a continuous glucose monitoring system (receiver and transmitter). The denial stated that the submitted documentation does not establish that the member is treated with an intensive insulin regimen as defined by policy, and does not establish that self-monitoring of blood glucose has been insufficient to guide therapy. The medical record satisfies the applicable criteria under NBH-ENDO-031-3 and NBH-ENDO-031-4 as follows: 1. Intensive Insulin Regimen (NBH-ENDO-031-3.1) Section NBH-ENDO-031-3.1 requires documented diagnosis of type 2 diabetes mellitus treated with an intensive insulin regimen consisting of three or more injections of insulin per day or continuous subcutaneous insulin infusion. The chart entry dated May 19, 2026, documents that the member is a 59-year-old man with type 2 diabetes mellitus of nine years' duration on a multiple daily injection regimen consisting of insulin glargine 38 units nightly plus insulin lispro three times daily with meals (four injections per day total), alongside metformin 1000 mg twice daily. 2. Device Training (NBH-ENDO-031-3.2 and NBH-ENDO-031-4.3) Section NBH-ENDO-031-3.2 requires documented training on the use and interpretation of the requested device, and section NBH-ENDO-031-4.3 requires submission of a record of device training. The diabetes education record dated June 11, 2026, documents that the patient and his spouse completed a forty-five minute structured training session on the use, application, calibration, and interpretation of the prescribed continuous glucose monitoring system. 3. Diabetes Management Evaluation (NBH-ENDO-031-3.3) Section NBH-ENDO-031-3.3 requires at least one in-person or telehealth evaluation with the treating clinician within the six months preceding the request at which diabetes management was addressed. The clinical record from July 14, 2026, documents an interim review evaluation pending device authorization at which diabetes management was discussed in full, recording an unchanged insulin regimen and fingerstick frequency of two to three per day. 4. Insufficiency of Fingerstick Self-Monitoring (NBH-ENDO-031-3.5) Section NBH-ENDO-031-3.5 requires documentation by the prescribing clinician that self-monitoring of blood glucose by fingerstick has been insufficient to guide therapy adjustment. The endocrinology note dated May 19, 2026, explicitly documents: "Because his overnight and mid-shift excursions are going undetected, fingerstick monitoring at the frequency he is able to sustain is insufficient to guide safe titration of his mealtime insulin." 5. Clinical Note Requirements (NBH-ENDO-031-4.1) Section NBH-ENDO-031-4.1 requires a clinical note from the treating clinician dated within six months of the request stating diabetes type, current insulin regimen, and clinical rationale for continuous monitoring. The progress note dated May 19, 2026, documents the patient's type 2 diabetes diagnosis, his current four-injection daily insulin regimen, and the clinical rationale that fingerstick monitoring is insufficient to guide safe titration of mealtime insulin due to undetected overnight and mid-shift excursions. Based on the submitted documentation meeting each relevant policy criterion under NBH-ENDO-031-3 and NBH-ENDO-031-4, we request that Northbeck Health Plan overturn the denial and approve coverage for the continuous glucose monitoring system.

Requested action: Overturn the denial and approve coverage for the continuous glucose monitoring system (receiver and transmitter).

Every factual claim the letter makes about the patient

These are the sentences you are attesting to. If one of them is not true of this patient, reject the draft rather than co-signing it.

The patient is a 59-year-old man with type 2 diabetes mellitus of nine years' duration.
The patient is treated with a multiple daily injection regimen consisting of insulin glargine 38 units nightly plus insulin lispro three times daily with meals, four injections per day total, alongside metformin 1000 mg twice daily.
The treating clinician documented that because overnight and mid-shift excursions are going undetected, fingerstick monitoring at the frequency the patient is able to sustain is insufficient to guide safe titration of his mealtime insulin.
The patient and his spouse completed a forty-five minute structured training session on June 11, 2026, on the use, application, calibration, and interpretation of the prescribed continuous glucose monitoring system.
The patient had a clinical evaluation on July 14, 2026, where diabetes management was discussed in full, noting an unchanged insulin regimen and fingerstick frequency of two to three per day.

Section 4 of 4

Your co-sign

Waiting on the billing clerk and the ordering clinician. Nothing is transmitted until every required signature is present.

Not signed

Billing clerk

Confirms the paper trail: that the cited sections exist, that the quoted policy text matches its source, and that no claim outruns the matrix.

No approval recorded yet.
Not signed

Ordering clinician

Attests to the clinical argument: that the letter's account of the care and the chart is accurate. A clerk is not in a position to judge this.

No co-sign recorded yet.

Sign the clinical argument in attempt 3

Your signature is pinned to this drafting attempt. If the letter is rewritten afterwards, it does not carry your name until you sign the new one.

Your name Recorded on the case and in the audit log. Required.

Credential MD, DO, NP, PA, and so on. Required.

NPI (optional) Ten digits. Some payers reject an appeal signed without one.

Anything to add (optional) Stored on the case. Not sent to the payer.

Attestation

You are attesting to the medicine, not to the paperwork. Whether every citation resolves and every quotation matches its source is the clerk's confirmation, recorded separately.

I ordered this care, or I am authorised to sign for the clinician who did, and the clinical argument in this letter is accurate.

Recorded with your name, credential and the time, against drafting attempt 3.

If the clinical argument is wrong, do not co-sign it. Say so on the full case record, where the draft can be rejected and rewritten.